A randomised controlled trial investigating the effects of adjunctive low-level laser therapy on gingival crevicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor-b ligand in the nonsurgical management of periodontitis.

Effect of adjunctive low level laser therapy on gingival crevicular fluid levels of sclerostin, osteoprotegerin and receptor activator of nuclear factor- Îºb ligand in the non surgical management of periodontitis - a randomized controlled trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/04/041773

Enrollment

Registered

2022-04-11

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Application of low level laser therapy.: Application of low-level laser therapy-After the initial treatment, patients in group 2 will receive LLLT using a diode laser (980nm) with the

Eligibility

Inclusion criteria

Inclusion criteria: Groups 1 and 2 Systemically healthy male and female subjects in the age group of 20 to 60 years. Presence of a minimum of 20 teeth in the oral cavity. Generalised periodontitis in stage3 gradeB as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and published by the American Academy of Periodontology (AAP). Group 3 Systemically healthy male and female subjects in the age group of 20 to 60 years. Presence of a minimum of 20 teeth in the oral cavity. Periodontally healthy controls i.e clinically healthy gingiva with intact periodontium characterized as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions and published by the American Academy of Periodontology (AAP).

Exclusion criteria

Exclusion criteria: Patients with a history of systemic diseases including bone-related and collagen-metabolic disorders that compromise sclerostin, OPG, or RANKL levels. Patients on steroid therapy or any other medications affecting bone metabolism. Current and former smokers. Chronic consumers of alcohol. Pregnant or lactating women. Subjects with intake of systemic antibiotics and anti-inflammatory drugs 3 months prior to their recruitment into study. Subjects with a history of periodontal therapy in any form 6 months prior to their recruitment to the study.

Design outcomes

Primary

Measure	Time frame
Primary outcome variables comprising of GCF levels of sclerostin, OPG and RANKL. Timepoint: Baseline,6thweek,3rdmonth.	—

Secondary

Measure	Time frame
Secondary outcome variables comprising of plaque index, gingival index, probing pocket depth and clinical attachment levelTimepoint: Baseline,6thweek,3rdmonth.	—

Countries

India

Contacts

Public ContactDr KEERTHANA CHAND CS

K.L.E Societys Institute of Dental Sciences

drveenahr@gmail.com9480516011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026